References Muller, T.D., Finan, B., Bloom, S.R., et
These medications not only assist with weight loss but also play a vital role in weight maintenance over time
For where these oral and higher-dose options sit among the candidates now in development, see the 2026 GLP-1 clinical pipeline, part of the broader GLP-1 and metabolic disease picture
Presented at ADA's 77th Scientific Sessions, San Diego, California, USA
In phase 2 trials, 1-2% of retatrutide participants experienced biliary disorders, including cholecystitis (1 participant) and cholelithiasis (2 participants)
Many clinicians therefore prescribe Ozempic for weight loss for individuals with Type 2 diabetes who also have overweight or obesity